Ask AI
ProCE Banner Activity

How I Approach Immunotherapy in Older Patients With Endometrial Cancer

Clinical Thought
In this commentary, I discuss how molecular profiling has affected the treatment of endometrial cancer and ongoing clinical trials, with a focus on patients older than 65 years of age.

Released: April 29, 2022

Share

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Domenica Lorusso, MD, PhD, Prof

Head of Gynecological Oncology Medical Unit
Humanitas San Pio X
Full Professor of Obtetrics and Gynecology
Department of Biomedical Sciences, Humanitas University
Milan, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.